Brii BioSciences Limited (stock code: 2137.HK) is a biotechnology company founded in 2018, developing therapies for high unmet medical needs, notably hepatitis B virus infection. Operating in China and the United States, the firm focuses on innovative therapeutic candidates and has a pipeline of unique programs. It employs a visionary leadership team and aims to improve patient health through advanced biotech research.
Brii BioSciences is profiled on the APIs.io network. Tagged areas include Biotech, Monoclonal Antibodies, Infectious Diseases, Hepatitis B, and COVID-19.
Regulatory Posture applies to this provider. Its tags matched the
Horizontal (data, software, accessibility, platform) regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: brii-biosciences
name: Brii BioSciences
description: 'Brii BioSciences Limited (stock code: 2137.HK) is a biotechnology company founded in 2018, developing therapies
for high unmet medical needs, notably hepatitis B virus infection. Operating in China and the United States, the firm focuses
on innovative therapeutic candidates and has a pipeline of unique programs. It employs a visionary leadership team and aims
to improve patient health through advanced biotech research.'
url: https://www.briibio.com/api-evangelist/brii-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment pass 2026-10-06 (modular-v1; was harvest)
specificationVersion: '0.20'
created: '2026-10-06'
modified: '2026-10-06'
tags:
- Biotech
- Monoclonal Antibodies
- Infectious Diseases
- Hepatitis B
- COVID-19
- Neuroscience
- China
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: Hosts
url: hosts/brii-biosciences-hosts.yml
- type: TermsOfService
url: https://www.briibio.com/en/terms-of-use/
- type: PrivacyPolicy
url: https://www.briibio.com/en/privacy-statement/
- type: Leadership
url: https://www.briibio.com/en/company/leadership/
- type: DomainSecurity
url: security/brii-biosciences-domain-security.yml
- type: Website
url: https://www.briibio.com
apis: []
x-coverage:
state: none
reason: no-developer-program
method: derived
generated: '2026-10-06'
generator: derive-coverage.py (pre-flight evidence)
detail: the company publishes no developer documentation host and no machine-readable contract on its own domain
evidence:
- url: https://www.briibio.com
status: 200
- url: https://forgeglobal.com/brii-biosciences_stock/
status: 403
x-enrichment:
date: '2026-10-06'
status: enriched
artifacts_added: 5
pass: modular-v1
engine: identity=local,contract=local,surfaces=local,docs=local,regulatory=local
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →